Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Federico PiñeroManuel MendizabalEzequiel RidruejoFernando Herz WolffBeatriz AmeigeirasMargarita AndersMaría Isabel SchinoniVirginia ReggiardoAna PalazzoMaría VidelaCristina AlonsoLuisa SantosAdriana VarónSebastián FigueroaCecilia VistariniRaúl AdroverNora FernándezDaniela PerezFederico TannoNelia HernándezMarcela SixtoSilvia BorziAndres BrunoDaniel CocozzellaAlejandro SozaValeria DescalziClaudio EstepoAlina ZeregaAlexandre de AraujoHugo CheinquerMarcelo Silvanull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
Achieving SVR with DAA regimens was associated with a significant risk reduction in HCC. However, this risk remained high in patients with advanced fibrosis, thus demanding continuous surveillance strategies in this population.